B. Riley points out that Allogene Therapeutics (ALLO) and Verastem (VSTM) have not yet experienced significant market movements since the SPDR S&P BIOTECH (XBI) upward trajectory over the past two months. Both names could outperform in 2024 “as they are poised to release pivotal trial results next year, which should capture additional investor interest,” the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ALLO:
- Allogene presents comprehensive safety data of Phase 1 ALPHA/ALPHA2 trials
- Allogene Therapeutics Presents Comprehensive Safety Data of Proprietary Lymphodepletion Agent ALLO-647 at the 65th Annual Meeting of the American Society of Hematology
- Allogene Therapeutics initiated with bullish view at Citi, here’s why
- Allogene Therapeutics price target lowered to $12 from $23 at H.C. Wainwright
- Allogene Therapeutics (NASDAQ:ALLO) Blasts Up on Earnings, New Data
